Laser devices for vaginal rejuvenation: effectiveness, regulation and marketing

Blayne Welk, Erin Kelly
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023 · vol. 195(5) , pp. E195–E196 · doi:10.1503/cmaj.221208 · PMID:36746476 · PMC9904821 · W4319321304
Other OA: gold CC0
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-10-11 ⓘ

This paper reviews the effectiveness, regulatory status, and marketing of laser devices for vaginal rejuvenation, which emerged in the mid-2010s as potential treatments for genitourinary syndrome of menopause.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

KEY POINTS In the mid-2010s, vaginal energy devices (such as fractional CO2 lasers, erbium-doped yttrium aluminium garnet lasers [Er:YAG], diode lasers or radiofrequency ablation) emerged as a new potential treatment for genitourinary sydrome of menopause (GSM). A clinical diagnosis of GSM requires

My notes (saved in your browser only)

MeSH descriptors

Laser Therapy Rejuvenation Female Humans Lasers Marketing Vagina

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (13)

SciLite annotations

chemicals 4
erbium yttrium aluminium collagen

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:38:36.131610+00:00
scilite
last seen: 2026-05-18T04:26:01.642840+00:00
License: CC0 · commercial use OK